Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903863 · ClinicalTrials.gov registry record · NA
The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity
A NA study of Extracorporeal Membrane Oxygenation, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01903863: Completed NA study of Extracorporeal Membrane Oxygenation, sponsored by Duke University.
NCT01903863 is a NA study of Extracorporeal Membrane Oxygenation that has completed, run by Duke University. The registered enrollment target is 31 participants, below the 271-participant average among 5 other Extracorporeal Membrane Oxygenation trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903863, a NA study of Extracorporeal Membrane Oxygenation, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of scheduled fresh frozen plasma (FFP) administration on extracorporeal membrane oxygenation (ECMO) pump longevity in critically ill pediatric and neonatal patients. Almost all ECMO patients receive multiple FFP transfusions during their ECMO course. The investigator proposes that scheduled FFP may maintain pro and anticoagulation balance thus mitigating the need for expensive and dangerous ECMO pump changes. In addition, this may lead to less overall transfusion with all products (red blood cells, platelets, and FFP) if coagulation homeostasis is maintained. The subjects will be neonatal and pediatric patients requiring ECMO support for any reason in the pediatric and pediatric cardiac critical care units. Subjects will be randomized to receive every other day FFP infusions or FFP administration per current standard of care. ECMO pump longevity (hours) and FFP use will be compared between the two groups There is a small risk that study subjects may receive more FFP transfusions and therefore have the increased associated risks however it is also possible that these subjects may benefit from less ECMO circuit changes and/or fewer transfusions of all blood products.
Primary Outcome
The primary endpoint is the ECMO pump longevity (measured in hours). The life of the circuit was defined as start of that circuit to circuit change or decannulation from ECMO for each patient. Circuit life was measured in hours
Conditions Studied
Interventions
- BIOLOGICAL Fresh frozen plasma
Study Locations (1)
North Carolina
- Duke University Medical Center PICU and PCICU - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-04 |
| Phase | NA |
What the finished NCT01903863 record still lists
NCT01903863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 271-participant average among 5 other Extracorporeal Membrane Oxygenation trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Extracorporeal Membrane Oxygenation appearing as the primary indexed condition, and to 1 intervention - of which Fresh frozen plasma is the first listed.
NCT01903863 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01903863 about?
NCT01903863 is a clinical study titled "The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity". The purpose of this study is to assess the impact of scheduled fresh frozen plasma (FFP) administration on extracorporeal membrane oxygenation (ECMO) pump longevity in critically ill pediatric and neonatal patients. Almost all ECMO patients receive multiple FFP transfusions during their ECMO course....
What is the current status of trial NCT01903863?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2013-07. Estimated completion is 2016-04.
What conditions does trial NCT01903863 study?
This clinical trial studies the following conditions: Extracorporeal Membrane Oxygenation.
What interventions are being tested in trial NCT01903863?
The interventions under investigation include: Fresh frozen plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT01903863?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01903863 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extracorporeal Membrane Oxygenation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Progressive Rehabilitation Therapy in Patients With Advanced Lung Disease
ACTIVE NOT RECRUITING · NA
-
Trial of Indication-Based Transfusion of Red Blood Cells in ECMO
ACTIVE NOT RECRUITING · NA
-
Hydrogen's Feasibility and Safety as a Therapy in ECPR
RECRUITING · Phase 1
-
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
RECRUITING
-
Biomarkers of Brain Injury in Critically-Ill Children on Extracorporeal Membrane Oxygenation
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia